Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin + Pioglitazone in T2D
NCT00683878Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2008
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, double-blind trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (3 arms), sponsored by AstraZeneca. Primary endpoint: Adjusted Mean Change From Baseline in Hemoglobin A1C at 24 weeks. Started Jul 2008; status: completed.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00683878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00683878.